Media 280723

CTO Mr Craig Weller said on Aqua Phase studies revealing the absorption of CBD as more than 4 times greater than CBD in oil:
Bod has been sweating on the PK study for months. It needed to show improved bioavailability of 30% for the deal to proceed, it exceeded by a factor of 10, what this means is that if we ingest 100mg of CBD in oil, we will normally absorb 6-8% of the dose. With Aqua Phase, the CBD absorption is 32% This means we can either get a better response to the CBD or otherwise we can reduce the Aqua Phase dose – giving potentially less side effects and providing CBD raw material savings.
Company news: Althea; Bod; ECS Botanics; LGP; Live Verdure; Creso Pharma; Emyria; Medlab
24 Feb 2022
Published by: Cannabiz
ASX Health Stocks: Genetic Tech is now lab certified and begins rollout of its geneType Multi-Test
21 Feb 2022
Published by: Stockhead
Bod seeks to register its cannabis extract as food in the UK
21 Feb 2022
Published by: The Sentiment
Industry bodies flag concerns over CA Clinics’ new online ordering service
10 Feb 2022
Published by: Cannabiz
What Investors Should Know About Australia’s New CBD Rules
02 Feb 2022
Published by: Investing News Network
Cannabis being used to treat symptoms of Long Covid in new landmark trial
01 Feb 2022
Published by: The Mirror
Australian Cannabis Outlook 2022: Positive Signs for Sales and Patient Numbers
28 Jan 2022
Published by: Investing News Network